Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BMS-986458 |
| Trade Name | |
| Synonyms | BMS 986458|BMS986458 |
| Drug Descriptions |
BMS-986458 is an E3 ubiquitin ligase-dependent BCL6 degrader, which potentially inhibits tumor growth (Blood (2024) 144 (Supplement 1): 957). |
| DrugClasses | BCL6 Inhibitor 6 |
| CAS Registry Number | NA |
| NCIT ID | C202207 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BMS-986458 | BMS-986458 | 0 | 1 |
| BMS-986458 + Glofitamab-gxbm + Obinutuzumab | BMS-986458 Glofitamab-gxbm Obinutuzumab | 0 | 1 |
| BMS-986458 + Mosunetuzumab-axgb | BMS-986458 Mosunetuzumab-axgb | 0 | 1 |
| BMS-986458 + Rituximab | BMS-986458 Rituximab | 0 | 1 |